Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Company Growth (employees)
Cleveland, US
Size (employees)
60 (est)
Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Cleveland and Canton
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St

Athersys Data and Metrics

Athersys Financial Metrics

Athersys's revenue was reported to be $17.3 m in 2016
$, USD

Revenue (Y, 2016)

17.3 m

Revenue growth (Y, 2015 - Y, 2016), %


Net income (Y, 2016)

(15.3 m)

EBIT (Y, 2016)

(15 m)

Market capitalization (22-Jun-2017)

175.9 m

Closing share price (22-Jun-2017)


Cash (31-Dec-2016)

14.8 m


161.1 m
Athersys's current market capitalization is $175.9 m.
$, USDFY, 2013FY, 2014FY, 2015Y, 2016


2.4 m1.6 m11.9 m17.3 m

Revenue growth, %


Operating expense total

26.9 m30.6 m29.1 m33.1 m


(24.5 m)(29 m)(17.2 m)(15 m)

EBIT margin, %


Pre tax profit

(30.7 m)(22.3 m)(16.5 m)(15.4 m)

Income tax expense

253 k38 k37 k

Net Income

(30.7 m)(22.1 m)(16.4 m)(15.3 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


31.9 m26.1 m23 m14.8 m

Accounts Receivable

520 k694 k361 k598 k

Current Assets

32.9 m27.2 m23.8 m16.3 m

Total Assets

34.2 m28.7 m25.1 m19.1 m

Accounts Payable

2.2 m2.8 m2.7 m4.8 m

Total Debt

176 k183 k190 k

Current Liabilities

4.4 m4.7 m4.8 m6.9 m

Additional Paid-in Capital

284.3 m307.3 m322.6 m329.4 m

Retained Earnings

(264.4 m)(286.5 m)(302.9 m)(318.3 m)

Total Equity

19.8 m20.9 m19.7 m11.2 m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.7 x1.4 x1.3 x1.7 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(30.7 m)(22.1 m)(16.4 m)(15.3 m)

Depreciation and Amortization

346 k360 k267 k382 k

Accounts Receivable

(30 k)(174 k)333 k(237 k)

Accounts Payable

(196 k)335 k(296 k)2.4 m

Cash From Operating Activities

(22.8 m)(25.8 m)(13.8 m)(10.9 m)

Cash From Investing Activities

(385 k)(297 k)(132 k)(1.1 m)

Cash From Financing Activities

29.6 m20.3 m10.8 m3.7 m
Y, 2016


-10.7 x


-14.7 x

Financial Leverage

1.7 x

Athersys Operating Metrics

Athersys's Patent Applications was reported to be 170 in FY, 2016
FY, 2016

Patents Issued


Patents (US)


Patent Applications


Athersys Market Value History

Athersys Online and Social Media Presence

Athersys Company Life and Culture

You may also be interested in